中文

← All funding rounds

Cradle

EuropeProtein designAmsterdam, NetherlandsFounded 2021Private

Website · cradle.bio ↗

Software that uses protein language models to suggest better protein variants, which customers test in their own labs; Cradle also runs a wet lab to generate training data.

Disclosed total$97M + €5.5M≈ $103M · in USD at each round's date
Rounds on record3
Latest round$73MSeries B · 2024-11-26
Last stated valuationNone stated
Investors named7
Research on record2highest level 4 · Tested in the physical world

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date2023202420252026≈$5.68M$24M$73MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series B, 2024-11-26: the record then held no research entry for the company. The first research entry is dated 2024-12-08; the highest level so far is 4 (Tested in the physical world).

Rounds and research, on one timeline

  1. 2026-03-08
    Research

    Level 4 · Tested in the physical world

    Cradle's CRADLE-1 preprint claims protein lead optimisation 4-7 times faster than rational design, counted in wet-lab rounds

    Optimising a protein someone already has is what most lab work actually is, and the claim is counted in rounds of experiments rather than scores. What the 4-7 times is measured against is not in the abstract, and the campaigns behind it are the company's own work with its customers.

    Timeline entry →doi.org ↗

  2. 2024-12-08
    Research

    Level 4 · Tested in the physical world

    Cradle's redesigned cetuximab fragment binds EGFR at 1.2 nM, the best of 400 designs Adaptyv Bio tested

    An outside lab measured it, so the number is not Cradle's own. It improves an approved antibody rather than making a new binder: the loops that bind EGFR were kept. One design won, and Cradle says Adaptyv's computed ranking had placed its entries between 322nd and 623rd.

    Timeline entry →adaptyvbio.substack.com ↗

  3. 2024-11-26Series B
    Round

    $73M

    For: wet lab expansion, more data, better models, larger teams

    Wet labData generationModels and platform

    Company says total funding is now over $100M.

    Lead · IVP ✓Index Ventures ✓Kindred Capital ✓

    On the deal: Alex Lim (General Partner, IVP)

    Announced by the company · cradle.bio ↗

  4. 2023-11-28Series A
    Round

    $24M

    For: team growth, product and sales, lab and engineering space in Amsterdam

    HiringCommercial roll-outWet lab

    Company says this took total raised to $33M.

    Lead · Index Ventures ✓Kindred Capital ✓Chris Gibson (Recursion co-founder)Tom Glocer (former Thomson Reuters CEO)

    On the deal: Carlos Gonzalez-Cadenas (Partner, Index Ventures); Chris Gibson (Angel investor); Sofia Dolfe (Partner, Index Ventures); Tom Glocer (Angel investor)

    Announced by the company · cradle.bio ↗

  5. 2022-11-17Seed
    Round

    €5.5M≈ $5.68M

    For: product development, team, onboarding design partners

    Models and platformHiringCommercial roll-out

    The release gives €5.5M ($5.4M) and marks Cradle's exit from stealth.

    Co-lead · Index Ventures ✓Co-lead · Kindred Capital ✓Feike Sijbesma (former DSM CEO)Emily Leproust (Twist Bioscience founder)

    On the deal: Emily Leproust (Angel investor); Feike Sijbesma (Angel investor); Sofia Dolfe (Partner; co-led the investment, Index Ventures)

    Announced by the company · cradle.bio ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.